BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27149562)

  • 1. Progress in the mechanism and drug development of castration-resistant prostate cancer.
    Zuo M; Xu X; Li T; Ge R; Li Z
    Future Med Chem; 2016 May; 8(7):765-88. PubMed ID: 27149562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
    Fujimoto N
    Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
    Bastos DA; Dzik C; Rathkopf D; Scher HI
    Oncology (Williston Park); 2014 Aug; 28(8):693-9. PubMed ID: 25140626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further.
    Fujimoto N
    J UOEH; 2016 Jun; 38(2):129-38. PubMed ID: 27302726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
    Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
    Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
    [No Abstract]   [Full Text] [Related]  

  • 10. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer.
    Batra A; Winquist E
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):271-282. PubMed ID: 30422005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New therapies in metastatic castration resistant prostate cancer].
    Thibault C; Massard C
    Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.
    Wang S; Ekoue DN; Raj GV; Kittler R
    Cancer Lett; 2018 Dec; 438():86-96. PubMed ID: 30217566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
    Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
    Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives in the therapy of castration resistant prostate cancer.
    Rescigno P; Buonerba C; Bellmunt J; Sonpavde G; De Placido S; Di Lorenzo G
    Curr Drug Targets; 2012 Dec; 13(13):1676-86. PubMed ID: 23043326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
    Crona DJ; Milowsky MI; Whang YE
    Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer.
    Galletti G; Leach BI; Lam L; Tagawa ST
    Cancer Treat Rev; 2017 Jun; 57():16-27. PubMed ID: 28527407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
    Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G
    Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [ASC-J9 for castration-resistant prostate cancer].
    Yamashita S; Arai Y
    Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.